NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global...
-- Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth -- -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS...
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025...
-- Revenue expected to be approximately $100.0 million in FY 2025, representing growth of 25%-- --Revenue expected to be approximately $26.6 million in Q4 2025,...
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual J.P....
-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures --
-- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) -- -- 18-month data show a 77% median reduction in generalized...
--Data presentations to feature 18-month NAUTILUS results and new Post Approval Study (PAS) analyses on GTC seizure reduction-- --RNS ® System...
--Physician Fee Schedule (PFS) final rule substantially increases reimbursement for RNS neurostimulator implantation and replacement procedures-- --CY 2026 Outpatient...